CA2772614A1 - Composes et compositions pour le traitement du cancer - Google Patents
Composes et compositions pour le traitement du cancer Download PDFInfo
- Publication number
- CA2772614A1 CA2772614A1 CA2772614A CA2772614A CA2772614A1 CA 2772614 A1 CA2772614 A1 CA 2772614A1 CA 2772614 A CA2772614 A CA 2772614A CA 2772614 A CA2772614 A CA 2772614A CA 2772614 A1 CA2772614 A1 CA 2772614A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cancer
- independently selected
- ring
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27575409P | 2009-09-02 | 2009-09-02 | |
| US61/275,754 | 2009-09-02 | ||
| PCT/US2010/047615 WO2011028860A2 (fr) | 2009-09-02 | 2010-09-02 | Composés et compositions pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2772614A1 true CA2772614A1 (fr) | 2011-03-10 |
Family
ID=43625764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2772614A Abandoned CA2772614A1 (fr) | 2009-09-02 | 2010-09-02 | Composes et compositions pour le traitement du cancer |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2473506A4 (fr) |
| JP (1) | JP2013503888A (fr) |
| KR (1) | KR20120104165A (fr) |
| CN (1) | CN102625805A (fr) |
| AU (1) | AU2010289493A1 (fr) |
| BR (1) | BR112012004701A2 (fr) |
| CA (1) | CA2772614A1 (fr) |
| IN (1) | IN2012DN01878A (fr) |
| WO (1) | WO2011028860A2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101629642B1 (ko) | 2014-06-25 | 2016-06-13 | 서울대학교산학협력단 | 피퍼롱구민을 유효성분으로 함유하는 지방간 예방용 식품 조성물, 지방간 치료용 약학 조성물, 지방간 치료용 동물 의약품 및 사료 조성물 |
| GB201715008D0 (en) * | 2017-09-18 | 2017-11-01 | Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa | TRPV2 Antagonists |
| KR20200081633A (ko) | 2018-12-27 | 2020-07-08 | 주식회사 티에스디라이프사이언스 | 피퍼롱구민을 함유하는 담도폐쇄증 치료 또는 예방용 의약 조성물 |
| CN110002987B (zh) * | 2019-03-22 | 2020-09-15 | 南通大学 | 苯基亚烯丙基环己烯酮衍生物及制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101951768A (zh) * | 2007-02-14 | 2011-01-19 | 玛尔斯有限公司 | 神经原性化合物 |
| WO2008112195A1 (fr) * | 2007-03-09 | 2008-09-18 | Bioseek, Inc. | Méthodes d'identification d'agents et leur utilisation dans la prévention ou la stabilisation de la fibrose |
| CN102146054A (zh) * | 2010-02-10 | 2011-08-10 | 新昌县来益科技开发有限公司 | 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途 |
-
2010
- 2010-09-02 BR BR112012004701A patent/BR112012004701A2/pt not_active IP Right Cessation
- 2010-09-02 IN IN1878DEN2012 patent/IN2012DN01878A/en unknown
- 2010-09-02 CA CA2772614A patent/CA2772614A1/fr not_active Abandoned
- 2010-09-02 CN CN2010800418987A patent/CN102625805A/zh active Pending
- 2010-09-02 KR KR1020127007113A patent/KR20120104165A/ko not_active Application Discontinuation
- 2010-09-02 EP EP10814469A patent/EP2473506A4/fr not_active Withdrawn
- 2010-09-02 JP JP2012528029A patent/JP2013503888A/ja active Pending
- 2010-09-02 AU AU2010289493A patent/AU2010289493A1/en not_active Abandoned
- 2010-09-02 WO PCT/US2010/047615 patent/WO2011028860A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011028860A2 (fr) | 2011-03-10 |
| JP2013503888A (ja) | 2013-02-04 |
| IN2012DN01878A (fr) | 2015-08-21 |
| EP2473506A2 (fr) | 2012-07-11 |
| EP2473506A4 (fr) | 2013-03-06 |
| AU2010289493A1 (en) | 2012-04-19 |
| CN102625805A (zh) | 2012-08-01 |
| BR112012004701A2 (pt) | 2018-06-12 |
| KR20120104165A (ko) | 2012-09-20 |
| WO2011028860A3 (fr) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8349832B2 (en) | Compounds and compositions for treating cancer | |
| US8318737B2 (en) | Compounds and compositions for treating cancer | |
| JP5421340B2 (ja) | 癌治療のためのアジア酸またはアジアチコサイドの使用。 | |
| JP4172726B2 (ja) | シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤 | |
| AU720704B2 (en) | Conjugates of cis-docosahexaenoic acid and paclitaxel | |
| US20080125380A1 (en) | Fatty acid-anticancer conjugates and uses thereof | |
| US20090312373A1 (en) | Methods for the treatment of cancer using piperlongumine and piperlongumine analogs | |
| US20100129363A1 (en) | Methods and compositions using pde4 inhibitors for the treatment and management of cancers | |
| US10604510B2 (en) | Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof | |
| AU2013345007A1 (en) | Gemcitabine prodrugs and uses thereof | |
| CA2772614A1 (fr) | Composes et compositions pour le traitement du cancer | |
| US20130237539A1 (en) | Compounds and Compositions for Treating Cancer | |
| WO2000067802A1 (fr) | Compositions d'acides gras -n-substituted indol-3-glyoxyl-amide et leur utilisation | |
| CA2677813A1 (fr) | Procede de traitement des troubles proliferatifs cellulaires utilisant un secretagogue d'hormone de croissance | |
| EP2751141B1 (fr) | Inhibiteurs de pace4 stables à base de peptide | |
| US20060199835A1 (en) | Neuroprotective and anti-proliferative compounds | |
| KR100898330B1 (ko) | 항암성을 갖는 새로운 플라보노이드 유도체 7-ｏ-(3-벤질옥시프로필)-5,4' -ｏ-디메틸-아피제닌, 그 제법 및 그것을 포함하는 항암 조성물 | |
| US10646479B2 (en) | Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment for cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20150902 |